haloperidol decanoate has been researched along with hydroxychloroquine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Apramian, A; Kajani, R; Liu, A; Ubhayakar, N; Vega, A; Xu, P | 1 |
1 review(s) available for haloperidol decanoate and hydroxychloroquine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for haloperidol decanoate and hydroxychloroquine
| Article | Year |
|---|---|
Neuroleptic malignant syndrome in a COVID-19 patient.
Topics: Acute Kidney Injury; Antipsychotic Agents; Betacoronavirus; Bromocriptine; C-Reactive Protein; Coronavirus Infections; COVID-19; Dantrolene; Dopamine Agonists; Enzyme Inhibitors; Haloperidol; Humans; Hydroxychloroquine; Intensive Care Units; Leukocytosis; Lymphopenia; Male; Middle Aged; Muscle Relaxants, Central; Neuroleptic Malignant Syndrome; Pandemics; Pneumonia, Viral; Renal Dialysis; Respiration, Artificial; Rhabdomyolysis; SARS-CoV-2; Schizophrenia | 2020 |